the most common form of childhood cancer and represents one of the most radiationresistant forms of human malignancy. In this study, we examined the antileukemic efficacy of the B43 (anti-CD19)-pokeweed antiviral protein (B43-PAPI immunotoxin against radiation-resistant BCP leukemia cells. B43-PAP caused apoptosis of radiation-resistant primary BCP leukemia cells, killed greater than 999'0 of radiation-resistant primary leukemic progenitor cells from BCP leukemia patients, and con--CELL PRECURSOR (BCP) leukemia is the most common form of childhood cancer"6 and represents one of the most radiation-resistant forms of human malignancy."" Recent studies demonstrated that greater than 75% of clonogenic BCP leukemia cells from more than one third of the patients with newly diagnosed disease, and virtually all of the relapsed patients, are able to repair potentially lethal or sublethal DNA damage induced by radiation doses that correspond to the clinical total body irradiation (TBI) dose fractions (ie, 2 to 3 Gy)."" Consequently, the vast majority of high-risk BCP leukemia patients undergoing TB1 in the context of bone marrow transplantation (BMT) relapse within the first 12 months, and only 15% to 20% survive disease-free beyond the first 2 year^.^.".'^ Thus, the major challenge in BMT for BCP acute lymphoblastic leukemia (ALL) is the development of novel and more effective conditioning strategies.
ferred extended survival to severe combined immunodeficiency (SCID) mice xenografted with radiation-resistant human BCP leukemia. Furthermore, the combination of B43-PAP and total body irradiation (TBI) was more effective than TB1 alone in two SCID mouse bone marrow transplantation models of radiation-resistant human BCP leukemia. Thus, B43-PAP may prove useful in the treatment of radiationresistant BCP leukemia.
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ciency (SCID) mice xenografted with radiation-resistant human BCP leukemia. We also demonstrate that the combination of B43-PAP and TB1 is more effective than TB1 alone in two SCID mouse BMT models of radiation-resistant human BCP leukemia.
MATERIALS AND METHODS
B43-PAP irnrnunotoxin. PAP was isolated from spring leaves of pokeweed and purified by ion-exchange chromatography, as previously rep~rted.'~"~ PAP amino groups were thiolated using 2-iminothiolane, and modified PAP was mixed with SPDP-modified monoclonal antibodies (MoAbs) using a 3 5 1 molar ratio of PAP to MoAb to generate PAP immunotoxins in a sulfhydryl-disulfide exchange reaction.ls The immunotoxins were initially purified by gel filtration high performance liquid chromatography to remove unreacted PAP and high-molecular-weight (greater than 300 !dl) conjugates/aggregates.I5 CM-Sepharose ion-exchange chromatography was subsequently used to purify the immunotoxins from unconjugated MoAb, as previously described. 15 The procedures used for the large scale production of B43 MoAb in a dedicated ACUSYSTJr benchtop hollow-fiber celI culture system (Endotronics, Coon Rapids, MN), purification using the Affi-Prep Protein A MAPS system (Bio-Rad Laboratories, Hercules, CA), and conjugation to PAP have been previously described in detail.14. '5 Primay BCP leukemia cells. For the in vitro and in vivo analyses of the antileukemic activity of the B43-PAP immunotoxin, we used leukemia cell-enriched, cryopreserved bone marrow samples from six patients with relapsed BCP leukemia (provided by Dr K. Gajl-Peczalska, University of Minnesota Cell Marker Laboratory, Minneapolis, MN) and five patients with newly diagnosed t(4; ll)(q2l;q23)-canying BCP leukemia (provided by Dr W. Crist, St Jude Childrens Research Hospital, Memphis, TN) under the exemption category (45 CFR Part 46.101;b category 4 Existing data; Records review; Pathologic Specimens) in accordance with Department of Health and Human Services (DHHS) guidelines. These cryopreserved specimens were previously obtained from routine diagnostic bone marrow aspirates before standard therapy, and informed consent for treatment was obtained from parents, patients, or both based on DHHS guidelines.
In vitro treatment of primary BCP leukemia cells with B43-PAP immunotoxin or y-rays. Primary BCP leukemia cells (1 X 105/mL in alpha-minimal essential medium [MEM] supplemented with 5% [vol/vol] fetal bovine serum) were either (1) irradiated with 50 cGy, 100 cGy, 200 cGy, 400 cGy, and 800 cGy y-rays in a single exposure (100 cGy/min) using a "'CS irradiator, as previously described,' I ' or (2) treated for 8 hours at 37°C with 1,000 ng/mL B43-PAP immunotoxin. Controls included unirradiateduntreated cells as well as cells treated with 1,000 ng/mL G3.7 (anti-CD7)-PAP, a control im- for leukemic progenitor cell (LPC)-derived blast colony formation, as described.'"' The radiation survival curves were constructed, and the SF, (surviving fraction at 2 Gy) and alpha (a) values (initial slope reflecting the steepness of the linear component of cell killing in the linear-quadratic model of cell survival) were determined using computer programs for the analysis of cell survival data, as described.'"' According to radiation biology literature, a values 50.2 Cy" and SF2 values 20.5 are indicative of radiation resistance.'."
Apoptosis assays.
To detect apoptotic changes, radiation-resistant primary BCP leukemia cells were harvested 16 to 18 hours after continuous exposure to the B43-PAP immunotoxin (0.01, 0.1, 1.0, or 10.0 pg/mL) or the control immunotoxin TXU-PAP (1 or 10 pg/ mL) or irradiation with y-rays (2, 4, or 8 Gy). DNA was prepared from Triton-X-100 lysates for analysis of fragmentati~n.'~.'' In brief, equal numbers of cells were subjected to experimental treatments; lysed in hypotonic 10 mmol/L Tris-HC1 (pH 7.4). 1 mmoVL EDTA, 0.2% Triton-X-100 detergent; and subsequently centrifuged at 11,OOOg. This protocol allows the recovery of intact chromosomal DNA in the pellet and fragmented DNA in the supernatant. To detect apoptosis-associated DNA fragmentation, supernatants were electropheresed on a 1.2% agarose gel, and the DNA fragments were visualized by ultraviolet light after staining with ethidium bromide. In some experiments, cells were pretreated with excess Leu 12 (anti-CD19; 10 pg/mL) or control TXU (anti-CD7; 10 pg/mL) monoclonal antibodies before addition of B43-PAP to examine if the B43-PAPinduced apoptosis can be prevented specifically by occupation of the surface CD19 receptors with anti-CD19 antibody molecules.'6 LPC assays. Primary BCP leukemia cells (1 X lo5 cells/mL in a-MEM) were plated in duplicate 35-mm Petri dishes for a 7-day culture at 37°C in a humidified 5% CO2 atmosphere.'"' The medium was supplemented with 0.9% methylcellulose, 50 pmol/L 2-mercaptoethanol, 30% (voVvol) calf bovine serum (Hyclone Laboratories, Logan, UT), and 10% (voVvol) low-molecular-weight B-cell growth factor (Cellular Products, Buffalo, NY). On day 7, blast colonies containing greater than 20 cells were counted using an inverted phase microscope with high optical resolution. In each case, the whole Petri dish was counted to determine the number of LPCderived blast colonies. Colony cells were then subjected to morphologic and immunophenotypic analyses, as previously described.''.'' Cell lines. The radiation-resistant BCP leukemia cell lines NALM-6-UMl2"." and LC1:1922 were maintained by serial passages in RPM1 1640 medium (GIBCO Laboratories, Grand Island, NY) supplemented with 10% (vol/vol) heat-inactivated calf bovine serum (Hyclone Laboratories), 50 pglmL streptomycin, 50 IU/mL penicillin, 2 mmol/L L-glutamine, and 10 mmol/L Hepes buffer. Cells were cultured in tissue culture flasks at 37°C in a humidified 5% CO2 atmosphere. Before injection into SCID mice, cells were washed twice in phosphate-buffered saline (PBS) and resuspended in PBS at 25 X 106/mL. SCID mice were inoculated intravenously ([V) with 0.2 mL of these cell suspensions containing 5 X IO6 NALM-6-UMI or LC1;19 cells. SCID mice. All SCID mice were produced by specific pathogenfree (SPF) CB-l7 scidscid breeders (originally obtained from Dr Melvin Bosma, Fox Chase Cancer Center, Philadelphia, PA) and maintained in the American Association for Accreditation of Laboratory Animal Care (AAALAC)-accredited Research Animal Resources (RAR) SCID Mouse Facility of the Childrens Cancer Group ALL Biology Reference Laboratory at the University of Minnesota (Minneapolis, MN). SCID mice were maintained in a SPF environment in microisolator cages (Lab Products, Inc, Maywood, NY) containing autoclaved food, water, and bedding, as previously rep~r t e d . '~-~~ Trimethoprim/sulfamethoxazole (Bactrim; Lemmon CO, Sellersville, PA) was added to the drinking water of mice, which was changed three times a week. Mice were inoculated with 5 X IO6 leukemic cells via tail vein injections. Mice were observed daily for evidence of leukemia and killed when moribund or unable to obtain food or water. Event times were measured from the day of inoculation of leukemia cells to the day of paraplegia (which results from central nervous system [CNS] leukemia) or death. The probability of event-free survival was determined, and event-free interval curves were generated using the Kaplan-Meier product limit method, as previously rep~rted.~'-'~ We used the log-rank test to assess the effect of various treatment regimens on event-free survival of SCID mice, as previously
Mice were killed at 12 weeks or when they became moribund as a result of disseminated human BCP leukemia. Mice were necropsied at the time of death or euthanization, and histopathology, flow cytometry, and polymerase chain reaction (PCR) analyses were performed to assess their burden of human leukemia cells, as previously
For each mouse, multiple tissues, including bone marrow, spleen, liver, brain, kidneys, lungs, heart, ovaries, and gut, were histologically evaluated. All histopathologic studies were performed by a veterinary pathologist (ie, R.G.). B43 (anti-CD19)-phycoerythrin (PE), 9.4 (anti-CD45)-PE, and 2C3 (anti-1gM)-fluorescein isothiocyanate (FITC) antibodies and multiparameter flow cytometry were used to detect human BCP leukemia cells in the SCID mouse bone marrow cell suspensions, as reHuman DNA was detected by amplifying a 1 IO-bp fragment from the first exon of the human 0-globin gene, as described."
B43 (anti-CD19)-PAP immunotoxin treatment of SCID mice inoculated with radiation-resistant primary BCP leukemia cells. At 1 day after inoculation with primary t(4; 11) ALL cells, SCID mice were treated on 3 consecutive days with intraperitoneal (IP) bolus injections of B43-PAP (total dose: 30 pg per mouse, 1.5 m a g ) , as previously described.'" TB1 and syngeneic BMT. Groups of five SCID mice challenged with 5 X IO6 NALM-6-UM1 or LC1 ; 19 cells were placed in a circular plexiglass rotating jig and were subjected to 250 cGy TBI, as previously reported." The radiation dose was delivered at a rate of 63 cGylmin using a "' CS irradiator (Model Mark 1-68; J.L. Shephard and Assoc, Glendale, CA). At 24 hours after TBI, 15 X IO6 nucleated bone marrow cells (in 0.5 mL PBS) from healthy syngeneic SCID mice were injected IV via the tail vein. Syngeneic donor marrow was collected by flushing it from the shafts of femurs and tibias of healthy SCID mice into 15-mL centrifuge tubes using a 27-gauge needle on a I -m L syringe filled with sterile PBS supplemented with 2.5% (vol/vol) fetal bovine serum. A single-cell suspension of syngeneic SCID mouse bone marrow was prepared by gentle pipetting. Controls consisted of irradiated healthy SCID mice not challenged with BCP leukemia cells.
TBI plus B43-PAP radioimmunotherapy and syngeneic BMT. NALM-6-UM1 or LC1;19 cells (5 X IO6) were injected into the caudal vein of control mice (N = 15), which received PBS injections only, or test mice, which were subsequently treated with ( I ) 250 cGy TB1 (N = S ) , (2) 10 pg B43-PAP IP every day X 3 consecutive days (N = 51, or (3) a combination of (1) and (2), N = 5. All mice were transplanted IV via the tail vein with an inoculum of 15 x 1 Oh nucleated bone marrow cells (in 0.5 mL PBS) from healthy syngeneic SCID mice. The scheduling of these treatments was as follows: day 0, inoculation of leukemia cells 1V; day I , TBI; day 2, BMT; days 3, 4, and 5, B43-PAP or PBS IP. Fig 1, DNA from B43-PAP-treated primary BCP leukemia cells showed a ladder-like fragmentation pattern, consistent with apoptosis, whereas no DNA fragmentation was observed after exposure to 2 to 8 Gy y-irradiation. B43-PAP-induced apoptosis was mediated by the CD19-specific binding of the immunotoxin to leukemia cells because ( 1 ) prior incubation with excess unconjugated Leu12 (anti-CD19) antibody but not excess unconjugated TXU (anti-CD7) antibody prevented B43-PAP-associated DNA fragmentation in BCP leukemia cells, and (2) the anti-CD7 immunotoxin TXU-PAP did not cause apoptosis in these cells. Thus, B43-PAP induces apoptosis in BCP leukemia cells, and radiation resistance does not render CD19-positive leukemia cells resistant to the cytotoxicity of the B43-PAP immunotoxin. R43-PAP immutroto.xin kills radiation-resistant printan leukemic progenitor cells from patients with relapsed RCP leukemia. The activity of an agent against the bulk population of leukemia cells in apoptosis assays does not always predict its activity against the clonogenic self-renewing subpopulation of LPC. We next examined the in vitro antileukemic activity of the B43-PAP immunotoxin against primary LPC from six patients with relapsed BCP leukemia, including the four patients shown in Fig I . LPC from these four patients were highly resistant to y-rays, with SF2 values greater than 0.5 (range, 0.6 to 1 .O) and a-values 50.2 Gy" (range, 0 to 0.2 Gy"). B43-PAP killed 91 . l % to 99.9% of LPC regardless of their radiation sensitivity, whereas the control immunotoxin (33.7-PAP did not affect LPC-derived blast colony formation (Table l) .
RESULTS AND DISCUSSION

B43-PAP induces apoptosis
R43-PAP irnmunotoxin prevents development of overt leukemia in SClD mice inoculated with radiation-resistant prim a n leukemic cells from patients with newly diagnosed t(4; 11) RCP leukemia. We next examined the in vivo antileukemic activity of the B43-PAP immunotoxin against primary leukemia cells from five patients with newly diagnosed MLL-AF-4 fusion transcript-positive t(4; 11) leukemia. Leukemia cells from each case were radiation-resistant with avalues less than 0.1 Gy", and their CDIO-CDI9'sIgMimmunophenotype was consistent with BCP leukemia.
When injected IV into SCID mice that did not receive any subsequent treatment with B43-PAP, leukemia cells from all five patients caused histopathologically detectable overt leukemia with extensive multiple organ involvement (Table  2) . At the time of death, SCID mice with overt t(4; 1 1) leukemia were noted to have massive hepatosplenomegaly, lymphadenomegaly, enlarged kidneys, and enlarged ovaries. Histopathologically, densely packed leukemia-cell infiltrates were found in multiple organs (Table 2) . Multiparameter flow cytometric analyses of bone marrow, liver, and spleen lymphoid cells confirmed the abundance of CD19'CD45' sIgM-human ALL cells ( Table 2) . Presence of human DNA, Radiation sensitivity and 643-PAP sensitivity of primary LPC from patients with BCP leukemia were determined in colony assays, as described in Materials and Methods.
of the untreated SCID mice inoculated with primary blasts from these five t(4; 11) ALL patients developed disseminated leukemia, overt leukemia was not found in any of the B43-PAP-treated SCID mice that were challenged with primary blasts from the same patients (Table 2 ). Immunophenotypic studies were consistent with this histopathologic finding, in that the percentages of bone marrow cells expressing human CD19 or CD45 antigens were significantly lower in immunotoxin-treated, nonleukemic mice than in untreated, leukemic mice (Table 2) .
TBI plus B43-PAP immunotoxin is more effective than TBI alone against radiation-resistant human BCP leukemia in a SCID mouse BMT model system. We have previously reported that radiation-resistant NALM-6-UM1 cells" and E2A-PBX1 fusion transcript-positive LC1; 19 cells carrying a t(1; 19)(q23;p13) translocation** cause disseminated and invariably fatal BCP leukemia in SCID mice. We used these two SCID mouse models to examine the antileukemic efficacy of a TB1 plus B43-PAP radioimmunotherapy protocol. The strategy underlying the combined TB1 plus B43-PAP protocol was to subject xenografted human BCP leukemia in SCID mice first to the maximum tolerated dose of TB1 in the context of syngeneic BMT. After BMT to rescue the SCID mice from possible radiation-induced mortality, the mice were treated with B43-PAP immunotoxin at a dose level that yields clinically achievable systemic exposure levels in an attempt to eradicate the remaining fraction of radiation-resistant leukemic cells. As detailed below, combined radioimmunotherapy with TB1 plus B43-PAP was superior to T B 1 alone or B43-PAP alone in both SCID mouse BMT models. Female SClD mice were innoculated Iv with 5 x 10' priman/ bone marrow blasts from patients with newly diagnosed t(4;ll) BCP leukemia.
At 1 day after the innoculation with leukemia cells, half of the mice were treated with B43-pAp immunotoxin at a dose level (10 pg/mouse/d ~p X3 days, total dose. 30 kg/mouse) that was found to be safe in a recently completed phase I study in patients with relapsed ALL. Mice were electively killed at 12 weeks to assess the burden of human leukemia cells by histopathologic and flow cytometric examination, as described in Materials and Methods.
Abbreviations: BM, bone marrow; SPL, spleen; LIV, liver; BR, brain; KD, kidney; LU, lungs; HT, heart; OV, ovan/; GI, stomach and intestine; NE, not evaluated.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org In the first model system, 15 of 15 SCID mice injected IV with 5 X lo6 NALM-6-UM1 cells died of disseminated human BCP leukemia between 30 and 45 days (median survival, 37.8 days) (Fig 2A) . Treatments with a cumulative 30 pg IP dose of B43-PAP on days 3 through 5 ( P = .001) or 250 cGy T B 1 on day 1 ( P = .02) followed by syngeneic BMT on day 2 significantly extended survival of SCID mice. Specifically, B43-PAP-treated SCID mice died of leukemia between 41 and 50 days (median survival, 43.9 days), whereas SCID mice exposed to TB1 died of leukemia between 36 and 53 days (median survival, 45.5 days). By comparison, SCID mice treated with TB1 followed by B43-PAP died of leukemia between 49 and 69 days, with a median survival of 62.9 days (Fig 2A) , which is significantly longer than the median survival of PBS-treated mice ( P = .0001), B43-PAP-treated mice (P = .016), or mice exposed to TB1 only ( P = .022). In the second SCID mouse BMT model we used, 5 X lo6 LCl; 19 cells killed 15 of 15 mice between 25 and 46 days (median survival, 36.6 days; Fig 2B) . Treatment with B43-PAP (P = .001) or TB1 (P = ,006) followed by syngeneic BMT extended survival, reminiscent of the NALM-6-UM1 results. Specifically, B43-PAP-treated SCID mice died of leukemia between 48 and 73 days (median survival, 59.4 days), whereas SCID mice exposed to TB1 died of leukemia between 21 and 50 days (median survival, 47.4 days). SCID mice treated with TB1 followed by B43-PAP died of leukemia between 69 and 86 days, with a median survival of 82.3 days (Fig 2B) , which is significantly longer than the median survival of PBS-treated mice ( P = .0001), B43-PAP-treated mice ( P = .016), or mice exposed to TB1 only (P = .011).
To our knowledge, this study is the first to examine the antileukemic efficacy of an immunotoxin against radiation-resistant BCP leukemia cells. Previous studies have demonstrated that B43-PAP is a potent antileukemic immunotoxin.20*21 At nontoxic doses, this immunotoxin kills greater than 99% of human BCP leukemia cells in SCID achieved by standard or investigational chemotherapeutic agents, including cyclophosphamide, carmustine, etoposide, topotecan, cytarabine, taxol, vincristine, methylprednisone, doxorubicin, or L-asparaginase." Here, we provide experimental evidence that B43-PAP triggers apoptosis in radiation-resistant primary BCP leukemia cells, kills greater than 99% of radiation-resistant primary leukemic progenitor cells from patients with BCP leukemia, and confers extended survival to SCID mice xenografted with radiation-resistant MLL-AF4 fusion transcript-positive primary human BCP leukemia cells from children with t(4; 1 1 ) ALL. B43-PAP, when administered on days 3 through 5 after leukemic cell inoculation, was unable to prevent the development of fatal leukemia, but extended survival in SCID mice challenged with NALM-6 or LC1; 19 cell lines, which have a higher in vivo cloning efficiency than primary leukemic cells. Furthermore, the combination of B43-PAP and TBI was more effective than TB1 alone in two SCID mouse BMT models of radiationresistant human BCP leukemia. In the present study, B43-PAP was used at a total dose level of 1.5 mg/kg, which is lower than the maximum tolerated dose identified in a phase I study in patients with relapsed BCP leukemia.*' Thus, B43-PAP may prove useful in the treatment of radiation-resistant BCP leukemia. Despite the clinical radiation resistance of BCP leukemias, BMT remains the best prospect for survival of high-risk patients with BCP leuke~n i a .~' Combined or adjunctive therapies that exploit diverse cytotoxic mechanisms offered by biotherapy and chemotherapy may assist in the elimination of radiationresistant BCP leukemia cells. The results presented herein indicate that immunotoxins such as B43-PAP might be used in vivo in addition to TB1 as part of pre-BMT conditioning. 
